Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study in Patients with Hard-to-Heal Venous Leg Ulcers to Measure Efficacy and Safety of Locally Administered LL-37; A Phase IIb, Double-blind, Randomised, Placebo-controlled, Multi-centre Trial

Next Previous
X
Search
Trial Profile

A Study in Patients with Hard-to-Heal Venous Leg Ulcers to Measure Efficacy and Safety of Locally Administered LL-37; A Phase IIb, Double-blind, Randomised, Placebo-controlled, Multi-centre Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ropocamptide (Primary)
  • Indications Leg ulcer; Varicose ulcer
  • Focus Therapeutic Use
  • Acronyms HEAL LL-37
  • Sponsors ProMore Pharma

    • Most Recent Events

    • 31 Oct 2020 This trial has been completed in Poland, according to European Clinical Trials Database record.
    • 20 Oct 2018 Planned number of patients changed from 120 to 159.
    • 01 Oct 2018 According to a ProMore Pharma media release, first patient has been enrolled in this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top